CDC25A is overexpressed in many tumor cells and is associated with the malignancy and prognosis of several cancers, such as human glioma (Yamashita et al., 2010), retinoblastoma (Singh et al., 2015), breast cancer (Brunetto et al., 2013), and liver cancer (Lu et al., 2016). Here, CDC25A is linked to central nervous system cancer.